



ASX Announcement

Medlab Clinical Company Update

SYDNEY, August 03, 2023 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness is providing an important update.

Dear Shareholder,

The Board of Medlab writes to provide an update on the status of the Company.

The Board anticipates calling an Extraordinary General Meeting (EGM) during September 2023 (or soonest possible date), with details of associated transactions to be included in an Explanatory Memorandum accompanying the Notice of Meeting.

It is anticipated that the outcomes from this meeting will conclude the operations of the company.

We thank shareholders for their patience and will update accordingly.

Sincerely,
Sean Hall

- ENDS -

Medlab requests that shareholders nominate a contact email address to streamline provision of further information. Please provide the shareholders' name, holder identification number ("HIN") or securityholder reference number ("SRN"), and the desired email address to medlabshareholders@hallchadwick.com.au

Should you have any queries, please do not hesitate to contact our office at medlabshareholders@hallchadwick.com.au